



# Acne Vulgaris and the Facial Cutaneous Microbiome: A Cross-Sectional Pilot Study from the Annual Twins Day Festival

Justin W. Marson MD<sup>1</sup>, Paul Mouser PhD<sup>2</sup>, Stefano Berto PhD<sup>3</sup>, Hilary E. Baldwin MD<sup>4,5</sup>

<sup>1</sup>Department of Dermatology, SUNY Downstate Health Sciences University, Brooklyn, NY; <sup>2</sup>Acne Cure Alliance, Morristown, NJ; <sup>3</sup>Medical University of South Carolina, Charleston, SC; <sup>4</sup>Department of Dermatology, Rutgers Robert Wood Johnson, New Brunswick, NJ; <sup>5</sup>Acne Treatment and Research Center, Brooklyn, NY

## Synopsis

### Acne Vulgaris

Inflammatory dermatosis of the pilosebaceous unit<sup>1</sup> driven by:

- Follicular Hyperkeratinization
- Hyper-/Dys-seborrhea
- *Cutibacterium acnes* colonization
- Inflammation

Other intrinsic and extrinsic factors may affect acne severity including epidermal barrier dysfunctions<sup>2</sup>, high glycemic index diet<sup>3</sup>, and dysbiosis within the superficial and follicular microbiome<sup>4</sup>.

### Facial Cutaneous Microbiome

Superficial facial and truncal cutaneous microbiome are dominated by<sup>5</sup>:

- *Staphylococci* spp. (e.g. *S. epidermidis*): >27% of bacterial organisms
- *Propionibacterium* (including *Cutibacterium acnes*): <2%

Physiologically-healthy follicular microbiome<sup>6</sup> is more homogenous:

- *C. acnes* comprises 89-94% of the bacterial population, functioning as a commensal organism in healthy skin.

Additional microbes include

- *Malassezia* spp.
- Bacteriophages (including strains that specifically target *C. acnes*)

### Acne & Dysbiosis

Studies suggest pre-existing and treatment-associated transepidermal water loss (TEWL) may pathogenically alter the cutaneous microbiome.<sup>7,8</sup>

Additional factors that may instigate cutaneous dysbiosis include:

- age and physiologic changes associated with puberty<sup>9</sup>
- Colonization with virulent *C. acnes* phylotypes (e.g., IA1)<sup>6</sup>
- Elimination of commensal microbes with broad spectrum antibiotics<sup>10</sup>

## Objectives

1. To determine correlations between the facial cutaneous microbiome and the presence and severity of acne vulgaris.
2. To use questionnaire and survey data to identify potential environmental factors that may alter the facial cutaneous microbiome.

## Methods

Cross-sectional, IRB-approved study during a Pre-COVID-19 Twins Day Festival. Participants with and without acne were assessed by a board-certified dermatologist and completed a questionnaire regarding demographics, exercise, and environmental factors (e.g., pet ownership) and history of acne, acne treatment, and skin care regimen

Demographic analysis was performed using R. P-values were calculated based on t-test for pairwise comparisons or  $\chi^2$  test for multiple categories comparisons.

### Microbiome Assessment & Analysis

Superficial facial swabs of the forehead and malar cheeks were collected on-site. Microbiome data were collected and analyzed for 16S sequences clustered into Operational Taxonomic Units (OTUs) using the UPARSE algorithm. OTUs were mapped to an optimized version of the SILVA and UNITE Databases.

Analysis was performed using R. Custom script was used to identify trends in taxa abundance,  $\alpha$ -diversity, and  $\beta$ -diversity. Significance of categorical variables was determined using the non-parametric Mann-Whitney U test and/or the Kruskal-Wallis test. Ordination method was based on principal coordinates analysis (PCoA) followed by Monte Carlo permutation test for p-value estimation. Differential abundance was calculated using DESeq2. P-values were adjusted for multiple comparisons with Benjamini-Hochberg FDR correction.


## Results

**Table 1.** Participants' Characteristics: Acne v. Control

	Acne (N = 158)	Control (N = 64)	p-value
<b>IGA – n (%)</b>			
Mild	71 (53.0)	-	
Moderate	50 (37.3)	-	
Severe	13 (9.7)	-	
<b>Truncal Acne – n(%)</b>	61 (38.6)		
<b>Age – mean (SD)</b>	18.3 (6.0)	23.35 (10.7)	<.001
<b>Female Gender – n (%)</b>	123 (77.8)	47 (73.4)	.236
<b>BMI – mean (SD)</b>	22.8 (4.9)	25.5 (6.9)	0.002
<b>Fitzpatrick Score – mean (SD)</b>	3.01 (0.9)	3.00 (1.1)	.930
<b>Pets Now – n (%)</b>	115 (72.8)	40 (62.5)	0.066
<b>Exercise/Week – mean (SD)</b>	2.3 (1.7)	3.6 (2.2)	<.001
<b>Strenuous Exercise/Week – mean (SD)</b>	1.6 (1.5)	1.8 (1.7)	0.321


**Table 2.** Current use of Over the Counter and Prescription Topical and Systemic Agents

	Acne (n = 158)	Control (n = 64)	p-value
<b>Topical Products</b>			
Over the Counter, n(%)	8 (5.1)	0 (0)	.336
Benzoyl Peroxide, n(%)	54 (34.2)	3 (4.7)	<.001
Prescription Topicals, n(%)	36 (22.8)	3 (4.7)	<.001
<b>Systemic Treatments</b>			
Oral Contraceptive, n(%)	32 (20.3)	12 (18.8)	.401
Systemic Antibiotics, n(%)	17 (10.8)	0 (0.0)	0.003
Isotretinoin, n(%)	4 (2.5)	0 (0)	.100
<b>General Skin Care</b>			
Moisturizer, n(%)	88 (55.7)	34 (53.1)	.363
Cleanser, n(%)	115 (72.3)	40 (62.3)	.065
Sunscreen, n(%)	120 (75.9)	39 (60.9)	.012




**Figure 1.** Alpha diversity in the Facial Cutaneous Microbiome

P-Value: 0.009; R-Squared: 0.0356; F-Statistic: 4.36



**Figure 2.** Beta diversity in the Facial Cutaneous Microbiome



**Figure 3.** Differential Abundances of Bacterial Genera

## Results & Conclusions

1. Demographically, participants with acne:
  - Had mild-moderate acne (>90%)
  - Were younger ( $p < .001$ ) with a lower BMI ( $p = .002$ )
  - Exercised less frequently ( $p < .001$ )
2. Participants with acne were significantly more likely to have used
  - Benzoyl peroxide ( $p < .001$ )
  - Other prescription topicals ( $p < .001$ )
  - Systemic antibiotics ( $p = .003$ )
  - Sunscreen ( $p = .012$ )
3. Significant difference in Shannon diversity index ( $p = .04$ ) suggests decreased diversity in participants with acne than control
4. Significant difference in  $\beta$ -diversity suggests a significant ( $p = .009$ ) difference in composition of bacteria between participants with acne and control
5. Individuals with acne trended towards having increased relative abundance of *Propionibacterium* spp. and *Staphylococcus* spp..

Environmental factors, including acne therapy, UV exposure, and sweat may (indiscriminately and preferentially) alter the relative abundances and lead to decreased microbial diversity. Further studies are needed, especially of the follicular microbiome and *C. acnes* phylotypes, to study the role of dysbiosis in acne pathogenesis.

## References

1. Zaenglein et al. J Am Acad Dermatol. 2016 May;74(5):945-73.e33. doi: 10.1016/j.jaad.2015.12.037. Epub 2016 Feb 17. Erratum in: J Am Acad Dermatol. 2020 Jun;82(6):1576. PMID: 26897386.
2. Pappas, A. et al. 26<sup>th</sup> European Academy of Dermatology and Venerology (EADV) Congress: P0065. Presented 13-17 September 2017
3. Marson JW, Baldwin HE. Dermatol Clin. 2019 Apr;37(2):183-193. doi: 10.1016/j.det.2018.12.001. Epub 2019 Feb 14. PMID: 30850041.
4. Dagnelie MA, et al. Decrease in Diversity of Propionibacterium acnes Phylotypes in Patients with Severe Acne on the Back. Acta Derm Venereol. 2018 Feb 7;98(2):262-267. doi: 10.2340/00015555-2847. PMID: 29136261.
5. Dréno B, et al. C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018 Jun;32 Suppl 2:5-14. doi: 10.1111/jdv.15043. PMID: 29894579.
6. Fitz-Gibbon S. et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol 2013; 133: 2152–2160
7. Yamamoto A et al. Impaired water barrier function in acne vulgaris. Arch Dermatol Res. 1995;287(2):214-8. doi: 10.1007/BF01262335. PMID: 7763094.
8. Rocha MA, Bagatin E. Skin barrier and microbiome in acne. Arch Dermatol Res. 2018 Apr;310(3):181-185. doi: 10.1007/s00403-017-1795-3. Epub 2017 Nov 17. PMID: 29147769.
9. Shibagaki, N et al., 2017. Aging-related changes in the diversity of women's skin microbiomes associated with oral bacteria. Scientific Reports 7. doi:10.1038/s41598-017-10834-9
10. Dowell A, Barnard E, Nagy let al. An expanded multilocus sequence typing scheme for Propionibacterium acnes: investigation of 'pathogenic', 'commensal' and antibiotic resistant strains. PLoS One 2012;7: e41480

## Acknowledgements & Disclosures

We would like to acknowledge Diversigen, Inc. for their technical support. JWM has served as an advisory board member for La Roche-Posay. PM and SB have no relevant disclosures. HEB has the following relevant disclosures: Galderma, Almirall, Ortho, Vyne, Mayne, Sun, EPI Health, La Roche-Posay, J & J.